Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/28/2026, 12:00:00 AM
On April 28, 2026, AbbVie announced a strategic collaboration with Kestrel Therapeutics, including an exclusive option to acquire the company. The deal, potentially worth up to $1.45 billion, focuses on developing Kestrel's pan-KRAS cancer inhibitor.
Korean Translation
2026년 4월 28일, AbbVie는 Kestrel Therapeutics를 인수할 수 있는 독점 옵션을 포함한 전략적 협력 관계를 발표함. 최대 14.5억 달러 규모에 이를 수 있는 이 계약은 Kestrel의 pan-KRAS 암 억제제 개발에 중점을 둠.
Related Recent Events
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 fiscal 2027 earnings release is scheduled for May 20, 2026. Low importance assigned as the announcement of an earnings date typically results in ~1% price impact, scheduled.
5/20/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
First quarter 2026 financial results and conference call on May 11, 2026, with high importance estimated due to potential market impact of earnings guidance, scheduled.
5/11/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Earnings Release
First quarter 2026 financial results on May 7, 2026, to be released after market close; significant price impact expected based on recent growth trends scheduled.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is expected to announce its Q1 2026 financial results scheduled. Scheduled earnings releases are key volatility events with an estimated 5% impact.
5/7/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
First quarter 2026 financial results and business update scheduled for May 5, 2026; high impact from potential 10% price volatility expected.
5/5/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
BioNTech will report first-quarter 2026 financial results and provide a corporate update on 2026-05-05; given the sharp March 2026 volatility after guidance and leadership news, this update is likely to be closely watched and could move shares materially, expected.
5/5/2026, 12:00:00 AM